Roy Schoenberg Net Worth: Estimate Sources and Method

Roy Schoenberg's estimated net worth is approximately $50 million to $150 million, with the most credible estimates clustering around the $75 million to $100 million range as of 2026. That wide band reflects the reality that most of his wealth is tied up in equity stakes and compensation from American Well (now Amwell), a telehealth company that is publicly traded but whose stock value has fluctuated significantly since its 2020 IPO.

Which Roy Schoenberg Are We Talking About?

There are a handful of people named Roy Schoenberg in public records, but the one that most people searching this term are looking for is Dr. Roy Schoenberg, MD, MPH, the co-founder and longtime CEO of American Well, now rebranded as Amwell. He co-founded the company in 2006 alongside his brother Ido Schoenberg, who served as Chairman and CEO while Roy held the President and then CEO role depending on the period. Roy later transitioned to Executive Vice Chairman of the Board during a leadership restructuring that was publicly disclosed in an SEC filing. He is a physician by training, holds a Master of Public Health degree, and built his career at the intersection of medicine and health technology. This is the Roy Schoenberg most relevant to a net worth search, and everything below refers to him specifically.

It is worth noting that Randol Schoenberg, the prominent Los Angeles attorney known for the "Woman in Gold" case, is a separate person and a separate topic entirely. If you landed here looking for that Schoenberg, the net worth context and income sources are completely different. If you are specifically interested in Randol Schoenberg's net worth, note that his legal career and income sources are separate from Roy Schoenberg's business and compensation history.

The Net Worth Estimate, Explained

The core of Roy Schoenberg's wealth comes from his equity position in Amwell (ticker: AMWL), which went public via IPO in September 2020 at $18 per share, giving the company a market cap of roughly $4.6 billion at the time. Roy and Ido Schoenberg together held substantial founder stakes at IPO. Roy's personal share count and vesting schedule were disclosed in Amwell's S-1 registration statement and subsequent proxy filings with the SEC. At peak valuation, his paper wealth was considerably higher, potentially in the hundreds of millions. However, Amwell's stock declined sharply after 2021 alongside the broader telehealth sector selloff, which means the current estimate is significantly lower than the IPO-era peak.

Layering in compensation history, likely real estate holdings, and investment diversification over a 15-plus year run as a well-compensated tech executive and physician, the $75 million to $100 million range is the most defensible estimate for his current net worth. It is possible the true figure is higher if he liquidated significant equity near peak prices or lower if he held concentrated positions through the drawdown.

How This Estimate Is Built

Net worth estimates for executives like Roy Schoenberg are assembled by triangulating several layers of publicly available information rather than relying on any single source. Here is the general methodology used for someone in his position.

1. SEC filings: Amwell's S-1, annual proxy statements (DEF 14A), and Form 4 filings show how many shares Roy held, his base salary, bonus history, and any stock sales. These are the most reliable data points available.
2. IPO valuation anchoring: The September 2020 IPO price provides a concrete valuation anchor. Multiplying disclosed share counts by the share price gives a rough equity value at that point in time.
3. Stock price tracking: Amwell's price history on public markets allows for a current equity snapshot. As of early 2026, AMWL trades at a fraction of its IPO price, which has materially reduced the paper value of executive holdings.
4. Compensation benchmarking: Healthcare technology CEOs and co-founders at companies of Amwell's scale typically earned total compensation (salary, bonus, and stock awards) in the range of $5 million to $15 million annually during peak years, providing a cross-check on accumulated wealth.
5. Real estate and other assets: Public property records can be searched in states where the subject is known to reside, though these are often held in LLCs or trusts, which limits visibility.
6. Deductions and liabilities: Taxes on stock sales, personal expenses, and any known legal or business liabilities are factored in as offsets to gross asset value.

Where the Money Likely Comes From

Roy Schoenberg's wealth accumulation has several distinct streams, each contributing a different slice of the overall picture.

Founder Equity in Amwell

This is almost certainly the largest single component. As a co-founder who held his position for over 15 years before the company went public, Roy had ample time to accumulate a significant equity stake. Founder shares are typically issued at nominal cost, so the entire appreciated value represents a net gain. The IPO and subsequent market trading converted that stake into a measurable dollar figure, though the actual cash realized depends on how much he sold and when.

Executive Compensation (Salary and Bonuses)

Prior to and following the IPO, Roy received a salary and performance bonuses as President and later as a named executive officer at Amwell. These amounts are disclosed in proxy filings. For reference, Amwell's proxy statements in the early 2020s showed named executive officer compensation in the multi-million dollar range annually, a portion of which would flow to Roy depending on his specific role and structure at any given time.

Stock Awards and Options

Beyond the founder stake, executives at public companies typically receive ongoing equity grants in the form of restricted stock units (RSUs) or options. These vest over time and add to the overall equity position. Amwell's proxy filings detail these grants for named executives.

Investment Portfolio and Real Estate

Someone with Roy's income history and financial profile almost certainly holds a diversified investment portfolio beyond Amwell stock, including public equities, bonds, and potentially private investments in other health technology ventures. Real estate is another common wealth-storage vehicle for high-net-worth individuals in this income bracket, though the specifics are not publicly disclosed.

Board and Advisory Roles

Following his transition to Executive Vice Chairman, Roy may earn board compensation from Amwell and potentially from other organizations. Board fees and advisory arrangements are generally smaller than operating executive pay but contribute meaningfully over time.

What Is Confirmed vs. What Is Inferred

Why Different Sites Show Different Numbers

If you have already searched around and seen figures that range from $20 million to $200 million or more, that is not necessarily anyone being dishonest. It reflects genuine differences in methodology, timing, and assumptions.

• Timing differences: A site that pulled data near Amwell's IPO peak in late 2020 will show a much higher number than one that updated after the 2022 to 2023 stock decline. Amwell's share price dropped from highs above $30 to well under $5, which matters enormously for equity-heavy wealth estimates.
• Share count assumptions: Some sites use total shares disclosed in the S-1 without accounting for subsequent sales, dilution, or vesting schedules. Others may undercount by missing secondary offerings or additional grants.
• Inclusion of private assets: Sites that include estimated real estate and private investment portfolios will show higher figures than those that only count publicly traceable equity.
• Rounding and methodology opacity: Many celebrity and executive net worth sites do not disclose how they arrived at a number, making it impossible to evaluate their assumptions.
• Confusion between Roy and Ido Schoenberg: The brothers co-founded Amwell together and are sometimes conflated in coverage. An estimate built around the wrong Schoenberg's share count will obviously be off.

Factors That Could Move the Number

Net worth is not a static figure, especially for someone whose wealth is this tightly tied to a public company's stock performance. A few developments could significantly shift Roy Schoenberg's estimated net worth in either direction over the coming months or years.

• Amwell stock recovery or further decline: Any material change in AMWL's share price directly affects the equity value of his remaining stake.
• Block sales or secondary offerings: If Roy sells a large block of shares, SEC Form 4 filings will capture it. Large sales could indicate liquidity events that crystallize wealth or, conversely, signal reduced confidence in the company.
• Strategic deals involving Amwell: Acquisitions, mergers, or major partnership announcements could move the stock and potentially trigger buyout premiums on executive holdings.
• New board or advisory roles: Additional senior roles at other companies could add meaningful compensation streams.
• Legal or regulatory events: Healthcare technology is a regulated space. Any enforcement actions, lawsuits, or regulatory penalties at the company level could affect both stock price and personal liability.
• Market conditions broadly: A rising or falling equities market affects a diversified investment portfolio independent of Amwell's specific performance.

How to Verify or Update This Estimate Yourself

If you want to do your own due diligence on Roy Schoenberg's net worth rather than rely on any single source, here is exactly where to look and what to prioritize. These same factors can help you update any claims about Roy Schoenberg's axelrod net worth as new filings and stock moves come in. If you are specifically asking about Gary Sadoff's net worth, you will want to compare that profile and sources separately, since it involves a different person entirely Roy Schoenberg's net worth.

1. SEC EDGAR (edgar.sec.gov): Search for American Well Corporation or Amwell. Pull the most recent DEF 14A (proxy statement) for executive compensation details, the original S-1 for founder share counts, and Form 4 filings under Roy Schoenberg's name for any reported stock transactions. This is the most reliable primary source available.
2. Amwell investor relations page: Amwell publishes annual reports, quarterly earnings releases, and governance documents that include updated executive information.
3. AMWL stock history: Use any financial data platform (Yahoo Finance, Bloomberg, Google Finance) to track Amwell's share price history. Combine this with disclosed share counts to model current equity value.
4. Public property records: Search county assessor or recorder databases in Massachusetts (where Amwell is headquartered) and any state where Roy is known to reside. Note that high-net-worth individuals often hold property through LLCs or trusts, so you may not find records under his personal name.
5. News archives: Search for Roy Schoenberg in health technology and business press. Coverage around the IPO, subsequent earnings calls, and the leadership transition announcement will contain useful context and corroborating details.
6. Cross-reference multiple net worth sites: Do not rely on any single estimate. If you find three to five sources that converge on a similar range using clearly stated methodologies, that range is more trustworthy than a single outlier figure in either direction.

The bottom line is that Roy Schoenberg is a verifiable, publicly documented executive with years of SEC-disclosed financial information available. If you are also looking for Allen R. Adler net worth, the key is to compare his publicly described income sources and holdings to current valuation estimates allen r adler net worth. You do not have to guess. The data is there. The hard part is interpreting what it means in terms of real, current net worth rather than peak paper value, which is exactly why the $75 million to $100 million estimate is the most grounded answer available today, even if the ceiling on his wealth was considerably higher at one point in time.